Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Business Wire
Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of VeriSeq™ NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu. VeriSeq NIPT Solution v2 delivers the most comprehensive view of the fetal genome compared to other CE-IVD NIPT products, enabling healthcare providers to support expectant parents with informed, timely and personalized pregnancy management options better than ever before. VeriSeq NIPT Solution v2 is now available across most countries in Europe,
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- United States Liquid Biopsy Market Analysis Report 2024: A $3.68 Billion Industry by 2032 from $1.06 Billion in 2023 - Emphasis on Companion Diagnostics, Increasing acceptance of Non-invasive Techniques [Yahoo! Finance]Yahoo! Finance
- Global Targeted Sequencing Industry Research 2023-2033: Burgeoning Opportunities Adoption in Targeted Therapeutics in Oncology and Use in Clinical Research and Trials for Better Disease Pathogenesis [Yahoo! Finance]Yahoo! Finance
- Multicancer Screening Market Projected to Reach $2.72 billion by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]Yahoo! Finance
- Illumina's planned divestment of GRAIL approved by the European Commission [Yahoo! Finance]Yahoo! Finance
- Illumina's planned divestment of GRAIL approved by the European CommissionPR Newswire
ILMN
Earnings
- 2/8/24 - Beat
ILMN
Sec Filings
- 4/12/24 - Form 8-K
- 4/10/24 - Form 4
- 4/9/24 - Form 8-K
- ILMN's page on the SEC website